Figure, Supplemental Digital Content 2. Study design

- Screening: Up to 21 days
- Pretreatment: 14 to 21 days
- Treatment period: 12 weeks
- Randomized withdrawal: 4 weeks

- Randomization (1:1)
- Site visits:
  - Week 0
  - Week 4
  - Week 8
  - Week 12
  - Week 16

- Linaclotide 290 μg
- Placebo
- Linaclotide 290 μg